CUSIP: 62921N105
Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
33,339,501
-
Share change
-
+767,802
-
Total reported value
-
$1,010,134,414
-
Price per share
-
$30.30
-
Number of holders
-
87
-
Value change
-
+$27,899,518
-
Number of buys
-
40
-
Number of sells
-
40
Quarterly Holders Quick Answers
What is CUSIP 62921N105?
CUSIP 62921N105 identifies NGM - NGM BIOPHARMACEUTICALS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2021
-
Previous quarter:
Q3 2020
Recent filing periods for CUSIP 62921N105:
Institutional Holders of NGM BIOPHARMACEUTICALS INC - COM (NGM) as of Q4 2020
As of 31 Dec 2020,
NGM BIOPHARMACEUTICALS INC - COM (NGM) was held by
87 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,339,501 shares.
The largest 10 holders included
Column Group LLC, BlackRock Inc., Euclidean Capital LLC, Point72 Asset Management, L.P., VANGUARD GROUP INC, Greenspring Associates, LLC, Ponoi II Management, LLC, Ponoi Management, LLC, Aquilo Capital Management, LLC, and STATE STREET CORP.
This page lists
87
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.